Comparative Pharmacology
Head-to-head clinical analysis: CHIRHOSTIM versus SEROSTIM LQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHIRHOSTIM versus SEROSTIM LQ.
CHIRHOSTIM vs SEROSTIM LQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic tripeptide (l-prolyl-l-lysyl-l-phenylalanyl) that stimulates phagocytosis via activation of mononuclear phagocytes and polymorphonuclear leukocytes through binding to formyl peptide receptors (FPRs), enhancing chemotaxis, superoxide production, and bactericidal activity. Also enhances natural killer (NK) cell activity and modulates cytokine release (e.g., IL-1, IL-6, TNF-α).
Recombinant human growth hormone (somatropin) that binds to growth hormone receptors, activating JAK-STAT signaling pathways, leading to increased insulin-like growth factor-1 (IGF-1) production, which promotes linear growth and anabolic effects.
Subcutaneous injection: 0.5 mg/kg once daily. Maximum dose: 40 mg/day.
0.2 mg/kg subcutaneously once daily for 4 weeks in HIV-associated wasting; for growth hormone deficiency, 0.005 mg/kg subcutaneously once daily initially, titrated to 0.01 mg/kg once daily.
None Documented
None Documented
Terminal elimination half-life is 14-16 hours; clinically, steady-state is achieved in approximately 3-4 days.
2.6 hours (subcutaneous administration); terminal half-life is approximately 2-3 hours, requiring daily dosing for growth hormone deficiency.
Primarily renal (70-85% as unchanged drug); biliary/fecal (10-20%) with enterohepatic recirculation.
Renal: >90% of somatropin is metabolized in the liver and kidneys; less than 1% of the administered dose is excreted unchanged in urine.
Category C
Category C
Growth Hormone
Growth Hormone